SCHEMBL3853102

SCHEMBL3853102

CCOC(=O)c1n[nH]c(=O)c(C(=O)OCC)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.56
PDE4D Q08499 1/20 0.51
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48
LMNA P02545 2/20 0.47
KDM4E B2RXH2 4/20 0.47
KDM5A P29375 1/20 0.46
KDM5B Q9UGL1 1/20 0.46
ADORA1 P30542 1/20 0.44
PDE1A P54750 1/20 0.44
PDE1B Q01064 1/20 0.44
PDE3B Q13370 1/20 0.44
PDE1C Q14123 1/20 0.44
PDE3A Q14432 1/20 0.44
MAPT P10636 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3849702 0.87 PDE4D (0.64) POLBPDE4DCYP1A2CYP2C19LMNA
SCHEMBL24761415 0.83 POLB (0.55) POLBPDE4DLMNAKDM4EADORA1
SCHEMBL3846991 0.80 PDE4D (0.47) POLBPDE4DCYP1A2CYP2C19LMNA
SCHEMBL4354885 0.80 PDE4D (0.47) POLBPDE4DCYP1A2CYP2C19LMNA
SCHEMBL3855819 0.80 PDE4D (0.47) POLBPDE4DCYP1A2CYP2C19LMNA
SCHEMBL3848316 0.79 KDM4E (0.52) POLBPDE4DCYP1A2CYP2C19LMNA
SCHEMBL4574454 0.79 PDE4D (0.46) POLBPDE4DCYP1A2CYP2C19LMNA
SCHEMBL20338259 0.78 PDE4D (0.66) POLBPDE4DCYP1A2CYP2C19KDM4E
SCHEMBL7254411 0.78 MAPT (0.63) POLBPDE4DCYP1A2CYP2C19KDM4E
SCHEMBL31367819 0.76 PDE4D (0.73) POLBPDE4DCYP1A2CYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2889289-A1 Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors GlaxoSmithKline LLC (US) 2015-07-01 EP disclosed
US-RE44613-E1 N-substituted glycine derivatives: hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2013-11-26 US disclosed
US-7608621-B2 Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production SMITHKLINE BEECHAM, CORP. (US) 2009-10-27 US disclosed
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors EGLN2, EGLN3, HIF1AN POLB 1401/4885PDE4D 4511/4885CYP1A2 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.